Extracellular Vesicles (EVs) are small membrane vesicles that are secreted by a multitude of cell types, which play a role in cell-to-cell communication. They can serve as clinically valuable tools for targeted treatment of multiple indications with a potential to make cell and gene therapies commercially viable for large populations.
From a manufacturing standpoint, EVs present unique challenges in both production and characterization. Developers work to address the robustness of their manufacturing processes, improve yield, and demonstrate the efficacy and potential of their EV-based therapies.
Lonza supports innovators across early and late stages with a science-driven framework for EV characterization to achieve clinical success, offering expertise in analytics, process development, and GMP-compliant manufacturing to advance candidates toward IND and commercialization.
Lonza's engEx® EV engineering technology enables therapeutic cargo to be tethered to the EV surface or loaded into the lumen via specialized scaffold proteins PTGFRN and BASP1, expanding the functional capabilities of extracellular vesicles to diverse therapeutic modalities and enhancing their potential as targeted delivery systems.
Lonza combines more than a decade of institutional hands-on EV experience with over 20 years in cell and gene therapy development and manufacturing, and uses this integrated skill set to support innovators from early development through late phase and commercial supply.
Vice President, Sales, Specialized Modalities
